|Mr. Steven Adam Lisi||CEO & Chairman||450k||N/A||1971|
|Mr. Amir Avniel||Co-Founder, Pres, COO & Director||400k||N/A||1974|
|Mr. Douglas J. Beck CPA||Chief Financial Officer||250k||N/A||1961|
|Mr. Adam Newman||Chief Legal Officer & Gen. Counsel||250k||N/A||N/A|
|Mr. Duncan Fatkin||Chief Commercial Officer||484.48k||N/A||N/A|
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.
Beyond Air, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.